文献速递慢性肾脏病血液净化与透析

硬骨抑素与慢性肾脏病:检测方法影响我们所(自以为)知道的

Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该分析研究比较了四种硬骨抑素检测方法(BM、TE、RD、MSD)在82例非透析患者和39例透析患者中的表现,发现不同方法测得的中位浓度差异巨大,方法间一致性差,且硬骨抑素与肾小球滤过率、年龄、性别、体重或甲状旁腺激素的关联因检测方法而异,提示临床推断受检测方法影响。

要点

  • 四种硬骨抑素检测方法测得浓度差异大,方法间一致性差。
  • 硬骨抑素与肾小球滤过率的负相关仅见于BM和TE法,MSD和RD法未见。
  • 硬骨抑素与年龄、性别、体重或甲状旁腺激素的关联因检测方法不同而异。

核心结论

  • 临床中关于硬骨抑素水平的推断在很大程度上受所用检测方法影响。

研究设计与样本

  • 分析研究,比较四种硬骨抑素检测方法(Biomedica、TecoMedical、R&D、MesoScaleDiscovery),纳入39例透析患者和82例非透析患者。

主要发现

  • 在82例非透析患者中,硬骨抑素中位浓度(pg/mL)分别为BM 984(IQR 648)、TE 629(IQR 237)、RD 154(IQR 84)、MSD 36(IQR 19)。
  • 检测方法间一致性相关系数较差(0.1-0.44)。
  • 透析患者中观察到相同的差异。
  • 肾小球滤过率与硬骨抑素(BM和TE法)呈显著负秩相关,但与MSD和RD法测值无显著相关。
  • 硬骨抑素与年龄、性别、体重或甲状旁腺激素的关联因检测方法不同而异。

临床怎么用

  • 临床解读硬骨抑素水平时需考虑检测方法的影响,不同方法结果不可直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sclerostin, a 22-kDa protein secreted by osteocytes, acts as a potent inhibitor of osteoblast activity. In chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular axis. However, large discrepancies between sclerostin assays have been described. METHODS: We compared four different assays [Biomedica (BM), TecoMedical (TE), R&D (RD) and MesoScaleDiscovery (MSD)] in an analytical study and addressed the question whether bioassay choice affects the correlation between circulating sclerostin and clinical and biochemical determinants. Circulating sclerostin levels were determined in 39 prevalent dialysis patients and 82 non-dialysis patients referred for glomerular filtration rate measurement. RESULTS: In the 82 non-dialysis patients, we observed large differences in median (interquartile range) sclerostin concentrations (in pg/mL): BM, 984 [interquartile range (IQR) 648]; TE, 629 (IQR 237); RD, 154 (IQR 84) and MSD, 36 (IQR 19). The concordance correlation coefficient between assays was poor (0.1-0.44). The same discrepancies were observed in dialysis patients. A significant negative rank correlation was found between glomerular filtration rate and sclerostin measured by BM and TE but not by MSD and RD. Associations between sclerostin and age, gender, weight or parathormone were also different according to the assay considered. CONCLUSIONS: Clinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Delanaye P, Paquot F, Bouquegneau A, et al. Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrol Dial Transplant. 2018. PMID: 29048521. doi:10.1093/ndt/gfx282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。